Pharmaceuticals

Daratumumab Or Darzalex Market 2026–2030: Forecasting Business Opportunities Ahead

March 5, 2026March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the daratumumab or darzalex market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Daratumumab Or Darzalex Market size between 2026 and 2035?

The market size for daratumumab or darzalex has seen rapid expansion in recent years. It is anticipated to increase from $5618.3 million in 2025 to $6189.36 million in 2026, demonstrating a compound annual growth rate (CAGR) of 10.2%. The historical growth of this market can be ascribed to factors such as its approval for multiple myeloma treatment, robust clinical outcomes specifically targeting cd38, the limited availability of alternative therapies for relapsed disease, widespread adoption by oncology centers, and enhanced patient survival rates.

The market for daratumumab or darzalex is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $9024.5 million by 2030, demonstrating a compound annual growth rate (CAGR) of 9.9%. Key factors driving this projected growth include the broader implementation of combination treatment plans, the increasing incidence of multiple myeloma, enhanced investment in oncology, the creation of novel therapeutic applications, and better patient access initiatives. Significant trends anticipated during this period encompass increased usage in multiple myeloma, its application in combination with other cancer medications, its integration into earlier stages of treatment, the administration of monoclonal antibody therapy within hospital settings, and its expanding utility across various hematologic malignancies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19896&type=smp

Which Drivers Are Impacting Market Performance In The Daratumumab Or Darzalex Market?

The increasing incidence of bone marrow cancer is anticipated to fuel the expansion of the daratumumab or darzalex market in the future. Bone marrow cancer encompasses malignancies that originate in the bone marrow, such as multiple myeloma and leukemia, where the production of abnormal blood cells interferes with normal bodily functions. This rise in bone marrow cancer cases can be attributed to an aging global population, enhanced detection methods, and contributing elements like environmental factors, lifestyle choices, and genetic predispositions. Daratumumab (Darzalex) aids in treating multiple myeloma, a specific type of bone marrow cancer, by targeting and eliminating abnormal plasma cells present in the bone marrow. For instance, in January 2025, the American Cancer Society, a US-based non-profit organization, projected that 2025 would see approximately 3,770 new instances of primary bone and joint cancer (2,150 in men and 1,620 in women), along with an estimated 2,190 deaths (1,240 in men and 950 in women). Consequently, the growing prevalence of bone marrow cancer is a key factor driving the growth of the daratumumab or darzalex market.

Which Segments Are Contributing To The Growth Of The Daratumumab Or Darzalex Market?

The daratumumab or darzalex market covered in this report is segmented –

1) By Drug Type: 100Mg Injection, 400Mg Injection

2) By Distribution Channel: Pharmacies, Hospital, Other Distribution Channels

3) By Application: Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Diffuse Large B Cell Lymphoma, Other Applications

Which Trends Are Shaping Activity Within The Daratumumab Or Darzalex Market?

Major companies operating in the daratumumab or darzalex market are redirecting their focus in oncology treatments towards early intervention approaches, such as combination therapies, to boost effectiveness in managing multiple myeloma and various other cancers. Combination therapies refer to treatment methodologies that utilize two or more therapeutic agents with differing mechanisms of action, often synergistically, to improve efficacy, minimize the development of resistance, and enhance patient outcomes, while also potentially reducing adverse effects compared to monotherapy. For example, in July 2024, Johnson & Johnson, a US-based pharmaceutical industry company, obtained U.S. FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in conjunction with bortezomib, lenalidomide, and dexamethasone (D-VRd) for both induction and consolidation therapy in patients diagnosed with newly diagnosed multiple myeloma (NDMM) eligible for autologous stem cell transplant (ASCT). This recent approval introduces a quadruplet therapy choice at the initial diagnosis stage, potentially leading to improved patient results.

Who Are The Prominent Global Companies Shaping The Daratumumab Or Darzalex Market Landscape?

Major companies operating in the daratumumab or darzalex market are Genmab A/S, Janssen Biotech Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/daratumumab-or-darzalex-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Daratumumab Or Darzalex Market?

North America was the largest region in the daratumumab or darzalex market in 2025. The regions covered in the daratumumab or darzalex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Daratumumab Or Darzalex Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19896&type=smp

Browse Through More Reports Similar to the Global Daratumumab Or Darzalex Market 2026, By The Business Research Company

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Rheumatoid Arthritis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report

Sarcoma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795